Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva M Riedmann

Showing results (51-60 of 95) with videos related to

Pageof 10
Sort By:
Human Vaccines & Immunotherapeutics|December 6, 2012
Update on NewLink's HyperAcute cancer immunotherapy productsEva M Riedmann
Human Vaccines & Immunotherapeutics|December 11, 2013
Two studies on optimal timing for measles vaccinationEva M Riedmann
Human Vaccines & Immunotherapeutics|May 20, 2014
Recently approved pandemic and seasonal influenza vaccinesEva M Riedmann
Human Vaccines & Immunotherapeutics|November 15, 2014
Combining the cancer vaccine DPX-Survivac with immune modulatorsEva M Riedmann
Human Vaccines & Immunotherapeutics|November 15, 2014
Stemline's synthetic multi-peptide cancer vaccine enters Phase 2Eva M Riedmann
Human Vaccines & Immunotherapeutics|November 27, 2014
Agenus’ brain cancer vaccine doubles survival rate in GBM patientsEva M Riedmann
Human Vaccines & Immunotherapeutics|November 27, 2014
Letter from the editorRonald Ellis, Eva M Riedmann
Human Vaccines & Immunotherapeutics|June 29, 2013
Bioinformatics analysis of H7N9 protein sequencesRonald Ellis, Eva M Riedmann
Human Vaccines & Immunotherapeutics|March 2, 2013
Letter from the editorRonald Ellis, Eva M Riedmann
Human Vaccines & Immunotherapeutics|September 10, 2013
Letter from the editorRonald Ellis, Eva M Riedmann
Pageof 10

Showing results (51-60 of 95) with videos related to

Sort By:
Pageof 10
Human Vaccines & Immunotherapeutics|December 6, 2012
Update on NewLink's HyperAcute cancer immunotherapy productsEva M Riedmann
Human Vaccines & Immunotherapeutics|December 11, 2013
Two studies on optimal timing for measles vaccinationEva M Riedmann
Human Vaccines & Immunotherapeutics|May 20, 2014
Recently approved pandemic and seasonal influenza vaccinesEva M Riedmann
Human Vaccines & Immunotherapeutics|November 15, 2014
Combining the cancer vaccine DPX-Survivac with immune modulatorsEva M Riedmann
Human Vaccines & Immunotherapeutics|November 15, 2014
Stemline's synthetic multi-peptide cancer vaccine enters Phase 2Eva M Riedmann
Human Vaccines & Immunotherapeutics|November 27, 2014
Agenus’ brain cancer vaccine doubles survival rate in GBM patientsEva M Riedmann
Human Vaccines & Immunotherapeutics|November 27, 2014
Letter from the editorRonald Ellis, Eva M Riedmann
Human Vaccines & Immunotherapeutics|June 29, 2013
Bioinformatics analysis of H7N9 protein sequencesRonald Ellis, Eva M Riedmann
Human Vaccines & Immunotherapeutics|March 2, 2013
Letter from the editorRonald Ellis, Eva M Riedmann
Human Vaccines & Immunotherapeutics|September 10, 2013
Letter from the editorRonald Ellis, Eva M Riedmann
Pageof 10